Rosetta Genomics (NASDAQ: ROSG) is one of 196 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it compare to its competitors? We will compare Rosetta Genomics to related businesses based on the strength of its risk, earnings, dividends, analyst recommendations, institutional ownership, valuation and profitability.
Volatility & Risk
Rosetta Genomics has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500. Comparatively, Rosetta Genomics’ competitors have a beta of 1.53, indicating that their average stock price is 53% more volatile than the S&P 500.
3.6% of Rosetta Genomics shares are owned by institutional investors. Comparatively, 48.7% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 14.0% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
This table compares Rosetta Genomics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Rosetta Genomics Competitors||-3,713.45%||-113.88%||-38.90%|
This is a breakdown of recent ratings and price targets for Rosetta Genomics and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Rosetta Genomics Competitors||504||2397||6509||122||2.66|
Rosetta Genomics presently has a consensus target price of $3.50, suggesting a potential upside of 386.11%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 18.15%. Given Rosetta Genomics’ stronger consensus rating and higher possible upside, analysts plainly believe Rosetta Genomics is more favorable than its competitors.
Earnings & Valuation
This table compares Rosetta Genomics and its competitors revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Rosetta Genomics||$9.23 million||-$16.23 million||-0.07|
|Rosetta Genomics Competitors||$220.75 million||-$39.68 million||-74.66|
Rosetta Genomics’ competitors have higher revenue, but lower earnings than Rosetta Genomics. Rosetta Genomics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Rosetta Genomics beats its competitors on 7 of the 12 factors compared.
Rosetta Genomics Company Profile
Rosetta Genomics Ltd. is engaged in developing and commercializing new diagnostic tests based on various genomics markers, including deoxyribonucleic acid (DNA), micro ribonucleic acid (microRNA) and protein biomarkers and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next Generation Sequencing (NGS) and Fluorescence In Situ Hybridization (FISH). It is marketing and selling over four diagnostic tests based on its microRNA technologies, which include RosettaGX Cancer Origin, mi-LUNG, mi-KIDNEY and RosettaGX Reveal. Its therapeutic pipeline consists of the projects, which include Rimonim Consortium and Magneton Project. It focuses on developing diagnostic assay, RosettaGX Reveal V2. It is also focusing on developing Bladder cancer risk stratification. Its PersonalizeDx is focused on the detection of genomic changes through FISH technology, which helps to detect cancer.
Receive News & Ratings for Rosetta Genomics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rosetta Genomics Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.